贝达药业：公司持有禾元生物5.6%股份

Group 1 - The company, Betta Pharmaceuticals, announced a commercial cooperation with Wuhan Heyuan Biotechnology Co., Ltd. for the regional commercialization of recombinant human albumin injection (rice-based) [1] - The recombinant human albumin product is considered groundbreaking, with clinical research showing efficacy comparable to human plasma albumin while overcoming safety risks associated with blood sources [1] - The company holds a 5.6% stake in Heyuan Biotechnology, which is currently under a lock-up period lasting one year post-IPO [1]